Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 1459 | 1.400 |
Why?
|
| Osteoporosis | 2 | 2023 | 133 | 1.320 |
Why?
|
| Pakistan | 11 | 2025 | 99 | 1.170 |
Why?
|
| Authorship | 1 | 2023 | 30 | 0.790 |
Why?
|
| Vitamin D | 3 | 2025 | 194 | 0.780 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2023 | 30 | 0.780 |
Why?
|
| Prediabetic State | 1 | 2023 | 68 | 0.720 |
Why?
|
| Practice Guidelines as Topic | 3 | 2025 | 1295 | 0.690 |
Why?
|
| Hypothyroidism | 1 | 2021 | 71 | 0.650 |
Why?
|
| Hyperprolactinemia | 1 | 2020 | 23 | 0.620 |
Why?
|
| Hip Fractures | 1 | 2021 | 64 | 0.620 |
Why?
|
| Vitamin D Deficiency | 1 | 2020 | 82 | 0.590 |
Why?
|
| Fractures, Bone | 1 | 2021 | 214 | 0.570 |
Why?
|
| Biomedical Research | 1 | 2023 | 561 | 0.520 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 895 | 0.370 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 889 | 0.360 |
Why?
|
| Vitamins | 2 | 2023 | 111 | 0.340 |
Why?
|
| Referral and Consultation | 2 | 2025 | 564 | 0.320 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2021 | 129 | 0.310 |
Why?
|
| Primary Health Care | 3 | 2025 | 775 | 0.310 |
Why?
|
| Humans | 22 | 2025 | 131163 | 0.260 |
Why?
|
| Blood Glucose | 2 | 2021 | 1117 | 0.240 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2025 | 15 | 0.220 |
Why?
|
| beta-Thalassemia | 1 | 2025 | 26 | 0.220 |
Why?
|
| Sri Lanka | 1 | 2024 | 10 | 0.210 |
Why?
|
| Phosphates | 1 | 2025 | 112 | 0.210 |
Why?
|
| Asia | 1 | 2024 | 124 | 0.210 |
Why?
|
| Graves Disease | 1 | 2024 | 13 | 0.210 |
Why?
|
| Hyperthyroidism | 1 | 2024 | 24 | 0.210 |
Why?
|
| Thyrotropin | 2 | 2021 | 50 | 0.190 |
Why?
|
| Health Facilities | 1 | 2023 | 66 | 0.190 |
Why?
|
| Respiration Disorders | 1 | 2023 | 30 | 0.190 |
Why?
|
| Bronchiectasis | 1 | 2023 | 22 | 0.190 |
Why?
|
| Education, Distance | 1 | 2024 | 69 | 0.190 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 3829 | 0.170 |
Why?
|
| Thyroid Neoplasms | 1 | 2024 | 241 | 0.170 |
Why?
|
| Technology | 1 | 2021 | 68 | 0.160 |
Why?
|
| Learning | 1 | 2024 | 356 | 0.160 |
Why?
|
| Disease Management | 1 | 2024 | 558 | 0.160 |
Why?
|
| Sulpiride | 1 | 2020 | 2 | 0.160 |
Why?
|
| Fructosamine | 1 | 2020 | 10 | 0.160 |
Why?
|
| Glycation End Products, Advanced | 1 | 2020 | 25 | 0.160 |
Why?
|
| Serum Albumin | 1 | 2020 | 101 | 0.150 |
Why?
|
| Palliative Care | 1 | 2024 | 443 | 0.150 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 263 | 0.150 |
Why?
|
| Perception | 1 | 2021 | 231 | 0.150 |
Why?
|
| Bone Density | 1 | 2021 | 367 | 0.140 |
Why?
|
| Students, Medical | 1 | 2022 | 347 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1445 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 650 | 0.120 |
Why?
|
| Prognosis | 1 | 2024 | 4886 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1118 | 0.110 |
Why?
|
| Asthma | 1 | 2023 | 922 | 0.110 |
Why?
|
| Registries | 1 | 2021 | 1634 | 0.100 |
Why?
|
| Female | 7 | 2025 | 70963 | 0.100 |
Why?
|
| Hyperparathyroidism, Primary | 2 | 2012 | 32 | 0.090 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2012 | 4 | 0.090 |
Why?
|
| Adult | 4 | 2023 | 31282 | 0.090 |
Why?
|
| Parathyroid Neoplasms | 1 | 2012 | 20 | 0.090 |
Why?
|
| Parathyroid Glands | 1 | 2012 | 26 | 0.090 |
Why?
|
| Hyperparathyroidism | 1 | 2012 | 21 | 0.090 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 83 | 0.090 |
Why?
|
| Receptors, Thyrotropin | 1 | 2011 | 7 | 0.090 |
Why?
|
| Obesity | 1 | 2023 | 2426 | 0.080 |
Why?
|
| Graves Ophthalmopathy | 1 | 2011 | 12 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2021 | 6459 | 0.080 |
Why?
|
| Adipogenesis | 1 | 2011 | 82 | 0.080 |
Why?
|
| Orbit | 1 | 2011 | 75 | 0.080 |
Why?
|
| Adipocytes | 1 | 2011 | 178 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 335 | 0.070 |
Why?
|
| Cushing Syndrome | 1 | 2008 | 22 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2009 | 139 | 0.070 |
Why?
|
| Aged | 3 | 2021 | 21025 | 0.060 |
Why?
|
| Hypophosphatemia | 1 | 2025 | 9 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 981 | 0.060 |
Why?
|
| Hyperphosphatemia | 1 | 2025 | 19 | 0.050 |
Why?
|
| Ferritins | 1 | 2025 | 104 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2021 | 17753 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2024 | 65 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2025 | 172 | 0.050 |
Why?
|
| Otolaryngology | 1 | 2025 | 118 | 0.050 |
Why?
|
| Educational Status | 1 | 2024 | 279 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2023 | 76 | 0.050 |
Why?
|
| Intention | 1 | 2022 | 105 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2024 | 320 | 0.040 |
Why?
|
| Homeostasis | 1 | 2025 | 712 | 0.040 |
Why?
|
| Career Choice | 1 | 2022 | 166 | 0.040 |
Why?
|
| Calcium | 1 | 2025 | 1010 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 730 | 0.040 |
Why?
|
| Algorithms | 1 | 2025 | 1680 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 115 | 0.020 |
Why?
|
| Body Fluids | 1 | 2012 | 45 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 101 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 4066 | 0.020 |
Why?
|
| Medical Records | 1 | 2012 | 174 | 0.020 |
Why?
|
| Adenoma | 1 | 2012 | 144 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2011 | 220 | 0.020 |
Why?
|
| Carcinoma | 1 | 2012 | 291 | 0.020 |
Why?
|
| Population | 1 | 2009 | 23 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 787 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1013 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1205 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 943 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 2085 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2008 | 215 | 0.020 |
Why?
|
| Male | 3 | 2025 | 64957 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2008 | 250 | 0.020 |
Why?
|
| Adolescent | 1 | 2025 | 20987 | 0.010 |
Why?
|
| Acute Disease | 1 | 2009 | 1153 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2885 | 0.010 |
Why?
|
| Child | 1 | 2025 | 26341 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5196 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2012 | 3711 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2009 | 3359 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 3360 | 0.010 |
Why?
|
| Middle Aged | 2 | 2012 | 28601 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 3147 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 6797 | 0.010 |
Why?
|